P16 as a HPV-Related Biomaker: Evaluation Its Correlation with the Proliferation Index (ki67) In Benign/Premalignant and Malignant Laryngeal Lesions

Noor alhuda H.Shaheed  Al-Fatlawi; Ahmed Mohammed Ali  Alshammari; Adel Sahib  Al-Mayaly

doi:10.17605/cajmns.v6i4.2886

Noor alhuda H.Shaheed Al-Fatlawi Jabir Ibn Hayyan University for Medical and Pharmaceutical sciences, Faculty of Medicine, Iraq
Ahmed Mohammed Ali Alshammari Jabir Ibn Hayyan University for Medical and Pharmaceutical sciences, Faculty of Medicine, Iraq
Adel Sahib Al-Mayaly Jabir Ibn Hayyan University for Medical and Pharmaceutical sciences, Faculty of Medicine, Iraq

DOI: https://doi.org/10.17605/cajmns.v6i4.2886

Keywords: HPV, Laryngeal lesions, P16 positivity, Ki67 expression, Immunohistochemistry (IHC), HPV-associated carcinoma

Abstract

Subsequent to lung cancer, laryngeal carcinoma is considered the second most common carcinoma within the aerodigestive region, representing about 20% of all H&N carcinomas. Laryngeal carcinoma is regarded as the most prevalent head and neck cancer within the Middle Euphrates regions. Recently, HR-HPV infection has been recognized as a potentially contributing factor in promoting LSCC progression. The co-expression of p16 and Ki67, the proliferation index, is considered a characteristic marker of HPV-driven cancers. The cross-sectional study involved 44 laryngeal lesions-benign, premalignant, and malignant-preserved as FFPE blocks that were classified in two main group: A) 21 sample with LSCC and B) 23 samples with benign/premalignant laryngeal lesions. Immunohistochemical analysis for p16 and Ki67, respectively. Statistical associations were evaluated using fisher’s exact and Chi square tests. P-value less than 0.05 was regarded as statistically significant. Significant correlation observed between p16 positivity and age, sex, lesion site, diagnosis, and Ki67. P16 immunohistochemical analysis is insufficient as a conclusive biomarker of HPV-driven laryngeal lesions.

References

Karatzanis AD, Psychogios G, Waldfahrer F, Kapsreiter M, Zenk J, Velegrakis GA, et al. Management of locally advanced laryngeal cancer. Journal of Otolaryngology-Head & Neck Surgery. 2014;43(1):4.

Megwalu UC, Sikora AG. Survival outcomes in advanced laryngeal cancer. JAMA Otolaryngology–Head & Neck Surgery. 2014;140(9):855–60.

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.

Mjali A, Hassan AK, Nassrullah HAA, Sedeeq AO, Abbas NT, Al-Shammari HHJ, et al. Pattern of Head and Neck Cancers in Karbala Province, Iraq: Data from a Developing Country. Asian Pacific Journal of Cancer Care. 2023;8(4):703–8.

Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 2013;4(1):66.

Yang QQ, Deng YF. Long non-coding RNAs as novel biomarkers and therapeutic targets in head and neck cancers. Int J Clin Exp Pathol. 2014;7(4):1286.

Yang D, Shi Y, Tang Y, Yin H, Guo Y, Wen S, et al. Effect of HPV infection on the occurrence and development of laryngeal cancer: a review. J Cancer. 2019;10(19):4455.

Scott-Wittenborn N, Fakhry C. Epidemiology of HPV related malignancies. In: Seminars in radiation oncology. Elsevier; 2021. p. 286–96.

Vazquez-Guillen JM, Palacios-Saucedo GC, Alanis-Valdez AY, Huerta-Escobedo A, Zavala-Pompa A, Rivera-Morales LG, et al. p16INK4a and pRb expression in laryngeal squamous cell carcinoma with and without infection by EBV or different genotypes of HPV: a retrospective study. Infect Agent Cancer. 2023;18(1):43.

Machczyński P, Majchrzak E, Niewinski P, Marchlewska J, Golusiński W. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. European Archives of Oto-Rhino-Laryngology. 2020;277:2407–12.

Bhardwaj S, Gitman M, Ramirez JD, Paniz-Mondolfi A, Westra WH. Reappraisal of p16 for determining HPV Status of Head and Neck Carcinomas arising in HPV hotspots. Am J Surg Pathol. 2024;48(5):581–7.

Tran NH, Sais D, Tran N. Advances in human papillomavirus detection and molecular understanding in head and neck cancers: Implications for clinical management. J Med Virol. 2024;96(6):e29746.

Mahajan A. Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol. 2016;51:64–74.

Munger K, Gwin TK, McLaughlin-Drubin M. p16 in HPV-associated cancers. Oncotarget. 2013;4(11):1864.

Linxweiler M, Bochen F, Wemmert S, Lerner C, Hasenfus A, Bohle RM, et al. Combination of p16INK4a/Ki67 immunocytology and hpv polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer. Cancer Cytopathol. 2015;123(4):219–29.

Gioacchini FM, Alicandri-Ciufelli M, Magliulo G, Rubini C, Presutti L, Re M. The clinical relevance of Ki-67 expression in laryngeal squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology. 2015;272:1569–76.

Kleist B, Junghans D, Lorenz G, Bankau A, Poetsch M. The supplementary diagnostic power of selected immunohistochemical, molecular genetic and infective parameters in epithelial hyperplastic laryngeal lesions. Oncology. 2003;65(4):347–54.

Şengiz S, Pabuççuoğlu U, Sarioğlu S. Immunohistological comparison of the World Health Organization (WHO) and Ljubljana classifications on the grading of preneoplastic lesions of the larynx. Pathology-Research and Practice. 2004;200(3):181–8.

Mylly M, Nissi L, Huusko T, Routila J, Vaittinen S, Irjala H, et al. Epidemiological study of p16 incidence in head and neck squamous cell carcinoma 2005–2015 in a representative northern European population. Cancers (Basel). 2022;14(22):5717.

Ribeiro EA, Maleki Z. p16 immunostaining in cytology specimens: its application, expression, interpretation, and challenges. J Am Soc Cytopathol. 2021;10(4):414–22.

Serra S, Chetty R. p16. J Clin Pathol. 2018;71(10):853–8.

Abi‐Raad R, Prasad ML, Gilani S, Garritano J, Barlow D, Cai G, et al. Quantitative assessment of p16 expression in FNA specimens from head and neck squamous cell carcinoma and correlation with HPV status. Cancer Cytopathol. 2021;129(5):394–404.

Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. Journal of clinical oncology. 2014;32(35):3930–8.

Meshman J, Wang PC, Chin R, John MS, Abemayor E, Bhuta S, et al. Prognostic significance of p16 in squamous cell carcinoma of the larynx and hypopharynx. Am J Otolaryngol. 2017;38(1):31–7.

Vazquez-Guillen JM, Palacios-Saucedo GC, Alanis-Valdez AY, Huerta-Escobedo A, Zavala-Pompa A, Rivera-Morales LG, et al. p16INK4a and pRb expression in laryngeal squamous cell carcinoma with and without infection by EBV or different genotypes of HPV: a retrospective study. Infect Agent Cancer. 2023;18(1):43.

Couture C, Raybaud‐Diogène H, Têtu B, Bairati I, Murry D, Allard J, et al. p53 and Ki‐67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94(3):713–22.

Chen W, Lin G, Chen Y, Cheng F, Li X, Ding J, et al. Prediction of the Ki-67 expression level in head and neck squamous cell carcinoma with machine learning-based multiparametric MRI radiomics: a multicenter study. BMC Cancer [Internet]. 2024 Apr 5;24(1):418. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12026-x

Beniwal A, Karwasra I, Parmar A, Beniwal HK, Sakhrani JK. Human Papillomavirus in Head and Neck Squamous Cell Carcinoma. Indian Journal of Surgery. 2018;80:322–6.

Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Annals of Oncology. 2017;28(10):2386–98.

GEIßLER C, Tahtali A, Diensthuber M, Gassner D, Stoever T, Wagenblast J. The role of p16 expression as a predictive marker in HPV-positive oral SCCHN–a retrospective single-center study. Anticancer Res. 2013;33(3):913–6.

Liu XY, Hanjing S, Zhang B huang, Luo XY. Expression of p16 and Ki67 in laryngeal squamous cell carcinoma and their clinical significance. Front Oncol. 2024;14:1430830.

Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92(2):276–84.

Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153(6):1741–8.

Laco J, Slaninka I, Jirásek M, Čelakovský P, Vošmiková H, Ryška A. High-risk human papillomavirus infection and p16INK4a protein expression in laryngeal lesions. Pathology-Research and practice. 2008;204(8):545–52.

Dogantemur S, Ozdemir S, Uguz A, Surmelioglu O, Dagkiran M, Tarkan O, et al. Assessment of HPV 16, HPV 18, p16 expression in advanced stage laryngeal cancer patients and prognostic significance. Braz J Otorhinolaryngol. 2020;86(3):351–7.